You are here: Industry Insights > Clovis

News List

FDA grants Clovis’ Rubraca fast track designation for prostate cancer pharmaceutical-technology
January 17, 2020
Colorado-based Clovis Oncology has received fast track designation from the US Food and Drug Administration (FDA) for Rubraca (rucaparib) as a monotherapy for BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer (mCRPC) adult patients.
Clovis should put itself up for sale, activist Armistice says fiercepharma
December 20, 2018
Even before GlaxoSmithKline laid out an eye-popping $5.1 billion to buy PARP drugmaker Tesaro earlier this month, analysts were speculating that PARP rival Clovis Oncology would be a prime acquisition target. One of the company’s largest investors apparen
Clovis loses Servier pact, agrees to settle SEC case fiercebiotech
August 03, 2018
Clovis Oncology has provided updates on two tarnished drugs that were once central to its plans. The biotech is set to put the rociletinib saga to bed through a $20 million agreement with the SEC, and it will also resume development of lucitanib without t
Clovis’ PARP inhibitor Rubraca under EU review in maintenance setting pharmatimes
July 16, 2018
European regulators have agreed to review Clovis’ application to expand the use of its PARP inhibitor Rubraca in the region.
Clovis’ PARP drug gets new US ovarian cancer use pharmaphorum
April 12, 2018
The FDA has granted Clovis Oncology’s rucaparib a new use in ovarian cancer, approving the PARP inhibitor as a maintenance therapy for women with recurrent disease.
New US approval for Clovis' Rubraca pharmatimes
April 10, 2018
Clovis' PARP inhibitor Rubraca has won a second US approval, as maintenance treatment for patients with recurrent ovarian cancer.
Clovis looks for new drugs after Rubraca success pharmaphorum
June 22, 2017
Clovis Oncology is in bullish mood following strong results from a late-stage study of ovarian cancer treatment Rubraca.